FDA issues 20 Warning Letters

Share this article:
The FDA has sent 20 Warning Letters to companies ordering them to stop marketing unapproved products containing ergotamine tartrate, which is used to treat vascular headaches. The action is part of FDA’s enforcement against makers of unapproved drugs.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.